POSTTRANSPLANT ORAL IRON-CHELATING THERAPY IN PATIENTS WITH beta-THALASSEMIA MAJOR

Yesilipek M. A., Karasu G., Kazik M., Uygun V., Ozturk Z.

PEDIATRIC HEMATOLOGY AND ONCOLOGY, cilt.27, sa.5, ss.374-379, 2010 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 27 Sayı: 5
  • Basım Tarihi: 2010
  • Doi Numarası: 10.3109/08880011003739463
  • Dergi Adı: PEDIATRIC HEMATOLOGY AND ONCOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.374-379
  • Anahtar Kelimeler: bone marrow transplantation, iron overload, thalassemia, BONE-MARROW-TRANSPLANTATION, SERUM FERRITIN, OVERLOAD, DEFERASIROX, BURDEN
  • Akdeniz Üniversitesi Adresli: Evet

Özet

Allogeneic hematopoetic stem cell transplantation (HSCT) is the only radical cure of beta-thalassemia. However, iron overload remains a cause of morbidity and mortality in posttransplant period. The authors present 7 patients as a preliminary report who underwent bone marrow transplant (BMT) and received oral chelating therapy (deferasirox) because of poor compliance to phlebotomy and desferrioxamine. The patients investigated mainly for possible side effects of deferasirox. No negative effect was seen in aspartate aminotransferase (AST), alanine aminotransferase (ALT), hemoglobin (Hb), and donor chimerism of the patients while serum ferritin levels significantly reduced (P = .018). Although serum creatinin significantly increased (P = .034), it was in normal limits in all patients. The authors believe that this report shows promising findings to plan further studies to clarify clinical safety and efficacy of deferasirox in posttransplant period.